source
- AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions🔎 AstraZeneca narrows path for failed antibody: The company announced last summer that its monoclonal antibody anselamimab missed the primary endpoint in a pair of Phase 3 trials for patients with…Endpoints · 2mo ago↗ source
- Replimune will again submit its melanoma drug for approvalThird time’s the charm? Replimune announced Friday that it will submit its advanced melanoma drug RP1 for FDA review after two prior rejections. It said it has had new discussions with ...Endpoints · 2mo ago↗ source
- Kenya court suspends U.S. plan for Ebola quarantine facility for AmericansA court in Kenya on Friday suspended a U.S. plan to establish a quarantine facility for Americans exposed to a rare type of Ebola virus spreading in northeastern Congo.